Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit

Cell Reports

Volumn 13, Issue 5, 2015, Pages 1016-1032

  Bertero, Thomas ^a,j   Cottrill, Katherine A ^a   Lu, Yu ^a   Haeger, Christina M ^a   Dieffenbach, Paul ^a   Annis, Sofia ^a   Hale, Andrew ^a   Bhat, Balkrishen ^b,k   Kaimal, Vivek ^b   Zhang, Ying Yi ^a   Graham, Brian B ^c   Kumar, Rahul ^c   Saggar, Rajan ^d   Saggar, Rajeev ^e   Wallace, W Dean ^d   Ross, David J ^d   Black, Stephen M ^f   Fratz, Sohrab ^g   Fineman, Jeffrey R ^h   Vargas, Sara O ⁱ   Haley, Kathleen J ^a   Waxman, Aaron B ^a   Chau, B Nelson ^b,k   Fredenburgh, Laura E ^a   Chan, Stephen Y ^a,l   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b REGULUS THERAPEUTICS   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BOSTON CHILDREN S HOSPITAL   (United States)

^j UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^k Translate Bio Inc   (United States)

^l UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; MICRORNA; MICRORNA 130A; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FEEDBACK SYSTEM; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; UPREGULATION; ANIMAL; C57BL MOUSE; GENETICS; MECHANOTRANSDUCTION; METABOLISM; PATHOLOGY; PH; SPRAGUE DAWLEY RAT;

ANIMALS; APOLIPOPROTEINS E; EXTRACELLULAR MATRIX; FEEDBACK, PHYSIOLOGICAL; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERTENSION, PULMONARY; LDL-RECEPTOR RELATED PROTEINS; MECHANOTRANSDUCTION, CELLULAR; MICE; MICE, INBRED C57BL; MICRORNAS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS;

EID: 84947433351     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.09.049     Document Type: Article

References (39)

1. Bertero T., Lu Y., Annis S., Hale A., Bhatt B., Saggar R., Saggar R., Wallace W.D., Ross D.J., Vargas S.O., et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J. Clin. Invest. 2014, 124:3514-3528.
2. Bertero T., Cottrill K., Krauszman A., Lu Y., Annis S., Hale A., Bhat B., Waxman A.B., Chau B.N., Kuebler W.M., Chan S.Y. The microRNA-130/301 family controls vasoconstriction in pulmonary hypertension. J. Biol. Chem. 2015, 290:2069-2085.
3. Bi R., Bao C., Jiang L., Liu H., Yang Y., Mei J., Ding F. MicroRNA-27b plays a role in pulmonary arterial hypertension by modulating peroxisome proliferator-activated receptor γ dependent Hsp90-eNOS signaling and nitric oxide production. Biochem. Biophys. Res. Commun. 2015, 460:469-475.
4. Boutet K., Montani D., Jaïs X., Yaïci A., Sitbon O., Simonneau G., Humbert M. Therapeutic advances in pulmonary arterial hypertension. Ther. Adv. Respir. Dis. 2008, 2:249-265.
5. Chan S.Y., Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J. Mol. Cell. Cardiol. 2008, 44:14-30.
6. Ciuclan L., Bonneau O., Hussey M., Duggan N., Holmes A.M., Good R., Stringer R., Jones P., Morrell N.W., Jarai G., et al. A novel murine model of severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2011, 184:1171-1182.
7. Cowan K.N., Heilbut A., Humpl T., Lam C., Ito S., Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 2000, 6:698-702.
8. Dufort C.C., Paszek M.J., Weaver V.M. Balancing forces: architectural control of mechanotransduction. Nat. Rev. Mol. Cell Biol. 2011, 12:308-319.
9. Dupont S., Morsut L., Aragona M., Enzo E., Giulitti S., Cordenonsi M., Zanconato F., Le Digabel J., Forcato M., Bicciato S., et al. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474:179-183.
10. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
11. Gan C.T., Lankhaar J.W., Westerhof N., Marcus J.T., Becker A., Twisk J.W., Boonstra A., Postmus P.E., Vonk-Noordegraaf A. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 2007, 132:1906-1912.
12. Hansmann G., de Jesus Perez V.A., Alastalo T.P., Alvira C.M., Guignabert C., Bekker J.M., Schellong S., Urashima T., Wang L., Morrell N.W., Rabinovitch M. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J. Clin. Invest. 2008, 118:1846-1857.
13. Huang Y., He Y., Li J. MicroRNA-21: a central regulator of fibrotic diseases via various targets. Curr. Pharm. Des. 2015, 21:2236-2242.
14. Im S.S., Osborne T.F. Liver x receptors in atherosclerosis and inflammation. Circ. Res. 2011, 108:996-1001.
15. Kerr J.S., Riley D.J., Frank M.M., Trelstad R.L., Frankel H.M. Reduction of chronic hypoxic pulmonary hypertension in the rat by beta-aminopropionitrile. J. Appl. Physiol. 1984, 57:1760-1766.
16. Kerr J.S., Ruppert C.L., Tozzi C.A., Neubauer J.A., Frankel H.M., Yu S.Y., Riley D.J. Reduction of chronic hypoxic pulmonary hypertension in the rat by an inhibitor of collagen production. Am. Rev. Respir. Dis. 1987, 135:300-306.
17. Kim K.M., Choi Y.J., Hwang J.H., Kim A.R., Cho H.J., Hwang E.S., Park J.Y., Lee S.H., Hong J.H. Shear stress induced by an interstitial level of slow flow increases the osteogenic differentiation of mesenchymal stem cells through TAZ activation. PLoS ONE 2014, 9:e92427.
18. Kothapalli D., Liu S.L., Bae Y.H., Monslow J., Xu T., Hawthorne E.A., Byfield F.J., Castagnino P., Rao S., Rader D.J., et al. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. Cell Rep. 2012, 2:1259-1271.
19. Lammers S., Scott D., Hunter K., Tan W., Shandas R., Stenmark K.R. Mechanics and Function of the Pulmonary Vasculature: Implications for Pulmonary Vascular Disease and Right Ventricular Function. Compr. Physiol. 2012, 2:295-319.
20. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
21. Lian I., Kim J., Okazawa H., Zhao J., Zhao B., Yu J., Chinnaiyan A., Israel M.A., Goldstein L.S., Abujarour R., et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010, 24:1106-1118.
22. Liu F., Lagares D., Choi K.M., Stopfer L., Marinković A., Vrbanac V., Probst C.K., Hiemer S.E., Sisson T.H., Horowitz J.C., et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015, 308:L344-L357.
23. Mecham R.P., Whitehouse L.A., Wrenn D.S., Parks W.C., Griffin G.L., Senior R.M., Crouch E.C., Stenmark K.R., Voelkel N.F. Smooth muscle-mediated connective tissue remodeling in pulmonary hypertension. Science 1987, 237:423-426.
24. Merklinger S.L., Wagner R.A., Spiekerkoetter E., Hinek A., Knutsen R.H., Kabir M.G., Desai K., Hacker S., Wang L., Cann G.M., et al. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circ. Res. 2005, 97:596-604.
25. Mouw J.K., Yui Y., Damiano L., Bainer R.O., Lakins J.N., Acerbi I., Ou G., Wijekoon A.C., Levental K.R., Gilbert P.M., et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat. Med. 2014, 20:360-367.
26. Nave A.H., Mižíková I., Niess G., Steenbock H., Reichenberger F., Talavera M.L., Veit F., Herold S., Mayer K., Vadász I., et al. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1446-1458.
27. Nickel N.P., Spiekerkoetter E., Gu M., Li C.G., Li H., Kaschwich M., Diebold I., Hennigs J.K., Kim K.Y., Miyagawa K., et al. Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling. Am. J. Respir. Crit. Care Med. 2015, 191:1273-1286.
28. Parikh V.N., Jin R.C., Rabello S., Gulbahce N., White K., Hale A., Cottrill K.A., Shaik R.S., Waxman A.B., Zhang Y.Y., et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012, 125:1520-1532.
29. Pencheva N., Buss C.G., Posada J., Merghoub T., Tavazoie S.F. Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell 2014, 156:986-1001.
30. Piccolo S., Dupont S., Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol. Rev. 2014, 94:1287-1312.
31. Poiani G.J., Tozzi C.A., Yohn S.E., Pierce R.A., Belsky S.A., Berg R.A., Yu S.Y., Deak S.B., Riley D.J. Collagen and elastin metabolism in hypertensive pulmonary arteries of rats. Circ. Res. 1990, 66:968-978.
32. Stenmark K.R., Rabinovitch M. Emerging therapies for the treatment of pulmonary hypertension. Pediatr. Crit. Care Med. 2010, 11(2, Suppl):S85-S90.
33. Valastyan S., Weinberg R.A. Roles for microRNAs in the regulation of cell adhesion molecules. J. Cell Sci. 2011, 124:999-1006.
34. Wang Z., Chesler N.C. Pulmonary vascular wall stiffness: An important contributor to the increased right ventricular afterload with pulmonary hypertension. Pulm. Circ. 2011, 1:212-223.
35. Wang D., Zhang H., Li M., Frid M.G., Flockton A.R., McKeon B.A., Yeager M.E., Fini M.A., Morrell N.W., Pullamsetti S.S., et al. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ. Res. 2014, 114:67-78.
36. Wei J., Bhattacharyya S., Jain M., Varga J. Regulation of matrix remodeling by peroxisome proliferator-activated receptor-γ: a novel link between metabolism and fibrogenesis. Open Rheumatol. J. 2012, 6:103-115.
37. White K., Loscalzo J., Chan S.Y. Holding our breath: The emerging and anticipated roles of microRNA in pulmonary hypertension. Pulm. Circ. 2012, 2:278-290.
38. Zhou J. An emerging role for Hippo-YAP signaling in cardiovascular development. J. Biomed. Res. 2014, 28:251-254.
39. Zhou Z., Hu T., Xu Z., Lin Z., Zhang Z., Feng T., Zhu L., Rong Y., Shen H., Luk J.M., et al. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J. 2015, 29:724-732.